Theratechnologies, a biopharmaceutical company focused on the development and commercialization of innovative therapies, drew down on its second tranche of $20 million under its credit agreement dated July 20, 2022, as amended, with certain funds and accounts for which Marathon Asset Management acts as investment manager.
The net proceeds of this second tranche, approximately $19.3 million, will be used to redeem all of the issued and outstanding $27.5 million 5.75% convertible unsecured senior notes due on June 30, 2023. The remaining balance will be funded from the company’s cash on hand.
The notes were issued under a trust indenture dated as of June 19, 2018, by and among Theratechnologies and Computershare Trust Company of Canada.
